A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Dulaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 16 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 24 Feb 2017 Planned End Date changed from 1 Oct 2017 to 1 Aug 2017.